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Summary
Background: An increased homocysteine (Hcy) concentra-
tion may represent a metabolic marker of folate and vita-
min B12 deficiency, both significant public health problems.
For different reasons, patients with chronic obstructive pul-
monary disease (COPD) are prone to these deficiencies.
The study evaluates the reliability of Hcy concentration in
predicting folate or vitamin B12 deficiency in these patients.
Methods: A group of 50 COPD patients (28 males/22
females, age (x⎯ ±SD=49.0±14.5) years was enrolled. A
chemiluminescent microparticle immunoassay was applied
for homocysteine, folate and vitamin B12 concentration.
Kolmogorov-Smirnov, Mann-Whitney U and c2 tests,
Spearman’s correlation and ROC analysis were included in
the statistical analysis, with the level of significance set at
0.05.
Results: Average (SD) concentrations of folate and vitamin
B12 were 4.13 (2.16) mg/L and 463.6 (271.0) ng/L,
whereas only vitamin B12 correlated with the Hcy level
(P=–0.310 (R=0.029)). Gender related differences were
not significant and only a borderline significant correlation
Kratak sadr`aj
Uvod: Povi{ena koncentracija homocisteina (Hcy) mo`e
predstavljati metaboli~ki marker nedostatka folata i vita -
mina B12, zna~ajnih problema javnog zdravlja. Bolesnici
sa hroni~nom opstruktivnom bole{}u plu}a (HOBP) skloni
su nedostatku ovih vitamina usled razli~itih razloga.
Prikazana studija procenjuje pouzdanost koncentracije Hcy
kao prediktora nedostatka folata i vitamina B12 kod ovih
bolesnika.
Metode: Studija je sprovedena u grupi od 50 osoba obo -
lelih od HOBP (28 mu{karaca/22 `ene, starosti (x⎯ ±SD=
49,0±14,5)  godina. Koncen tra cije Hcy, folata i vitamina
B12 su odre|ivane hemiluminiscentnim imunoodre|iva -
njem na mikro~esticama. Sta tisti~ka analiza je uklju~ila
testove Kolmogorov-Smirnov, Mann-Whitney U and c2,
Spearman-ovu korelaciju i ROC analizu, uz nivo zna~aj nosti
od 0,05.
Rezultati: Prose~ne (SD) koncentracije folata i vitamina B12
su iznosile 4,13 (2,16) mg/L i 463,6 (271,0) ng/L, pri
~emu je samo kod vitamina B12 uo~ena korelacija sa
nivoom Hcy (R=–0,310 (P=0,029)). Koncentracije vita -
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Introduction
Folate is essential for »one carbon units’ metab-
olism«, which generates intermediates necessary for
nucleic acid synthesis and methylation of various bio-
molecules (1). Vitamin B12 is required as the coen-
zyme to methylmalonyl-CoA mutase (EC 5.4.99.2)
and methionine synthase (EC 2.1.1.13), whereby the
second enzyme links the metabolism of these two »B
complex« vitamins (2). It catalyzes the conversion of
homo cysteine (Hcy) to methionine (Met) by virtue of
a methyl group transfer from the methyltetrahydrofo-
late. Deficiency of either vitamin can slow the reaction
and lead to deficient DNA synthesis, hyperhomocys-
teinemia (HHcy) and compromised methylation
potential (3).
World Health Organization (WHO) estimated
that folate and vitamin B12 deficiencies could be
encountered in millions of people throughout various
populations (3–5). Either of them may occur in sub-
clinical form, when vitamin depletion can be indicated
only through laboratory tests, and severe form in
which clinical symptoms become overt (3). In a major-
ity of cases, macrocytic anemia can be attributed to
severe folate and vitamin B12 deficiencies (6). A strong
causative relation has been established between
severe folate deficiency and neural tube defects,
adverse pregnancy outcomes, cognitive disorders in
elderly etc. Severe deficiency of vitamin B12 is evi-
denced as a significant risk factor for developmental
delay in childhood, neuropathy in adults and memory
and cognitive impairments in all ages (4, 7). Although
associated with cardiovascular disease, cancers and
osteoporosis, the significance of subclinical deficien-
cies is still not reliably evaluated (5, 8). Inadequate
folate intake is usually responsible for folate deficiency
and malabsorption for vitamin B12 deficiency (5).
Reliable laboratory assessment of folate and
vitamin B12 status is necessary to detect a deficiency,
develop a strategy for supplementation and monitor
its efficacy. Folate status is usually evaluated through
measurement of the folate concentration in
serum/plasma, indicating dietary intake, or erythro-
cytes, reflecting long-term status. Vitamin B12 con-
centrations in serum/plasma are considered a screen-
ing test in suspected deficiency, with holotranscobal-
amin measurement being recommended to improve
sensitivity (5). The utilization of metabolic markers in
assessment has been recommended by the WHO
since 2005 (6). HHcy may serve as an indicator of
both deficiencies. An increased level of methyl-
malonic acid is specific for vitamin B12 deficiency,
while the fraction of »unmetabolized folic acid« might
also be associated with impairment in the pathways
depending on both vitamins (3, 5). The initially pro-
posed cut-off values for the general population, based
upon the occurrence of HHcy (defined as a Hcy con-
centration above 10 or 12 mmol/L) as an indicator of
vitamin depletion, have undergone significant
changes. For folate, 4.0 mg/L (4) was increased to
6.6 mg/L (3, 9, 10) or even 8.0 mg/L (11), while to
consider vitamin B12 status as inadequate, cut-offs of
203 ng/L (3, 4) and 473 ng/L (9, 10) were used.
Patients with chronic obstructive pulmonary dis-
ease (COPD) are evidenced to be prone to folate and
vitamin B12 deficiency, supposedly due to the severe
nutritional impairments like increased basal meta bolic
rate, altered caloric intake, decreased body mass in -
dex accompanied with skeletal muscle loss. Further -
more, in certain populations an inverse relationship
between folate food intake and COPD risk was
observed. In studies investigating HHcy in these
patients the relationship between Hcy concentration
and vitamin intake or blood correlation was evaluat-
ed. Nevertheless, the ability of HHcy occurrence to
predict folate or vitamin B12 deficiency was not
addressed (12–15).
The study aims to provide an initial insight into
the reliability of Hcy concentration mea surement in
COPD patients for the purpose of detecting folate or
vitamin B12 deficiency. To achieve this, vitamin levels
in this group were correlated with the Hcy concen -
tration as well as with age and gender, the major
phy siological Hcy determinants (16). In addition, the
possibility of various Hcy concentrations to predict
folate or vitamin B12 deficiency in COPD patients was
analyzed.
between age and folate was confirmed (R=0.279
(P=0.047)). The incidence of folate and vitamin B12 defi-
ciency differed significantly (P=0.000 and P<0.000 for
folate and vitamin B12 respectively), depending on the cut-
off used for classification (4.4, 6.6 and 8.0 mg/L – folate;
203 and 473 ng/L – vitamin B12). ROC analyses failed to
show any significance of hyperhomocysteinemia as a pre-
dictor of folate or vitamin B12 deficiency.
Conclusion: Reliability of the Hcy concentration as a bio-
marker of folate or vitamin B12 depletion in COPD patients
is not satisfactory, so their deficiency cannot be predicted by
the occurrence of HHcy.
Keywords: homocysteine, folate, vitamin B12, COPD
mina se nisu razlikovale izme|u polova, a starost je bila u
korelaciji samo sa nivoom folata (R= 0,279 (P=0,047)).
Incidenca nedostatka vitamina zna~ajno se razlikovala
(P=0,000 i P<0,000 za folat odn. vitamin B12) u zavisnos-
ti od cut-off vrednosti u odnosu na koju je definisana (4,4;
6,6 i 8,0 mg/L – folat; 203 i 473 ng/L – vitamin B12). ROC
analizom nije bilo mogu}e dokazati zna~aj hiperhomocis-
teinemije kao prediktora deficijencije.
Zaklju~ak: Pouzdanost koncentracije Hcy kao markera
nedostatka folata ili vitamina B12 kod bolesnika sa HOBP
nije zadovoljavaju}a, pa se deficijencija ovih vitamina ne
mo`e predvideti na osnovu pojave hiperhomocisteine mije.
Klju~ne re~i: homocistein,  folat, vitamin B12, HOBP
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Materials and Methods
This cross-sectional study, approved by a com-
petent Ethics Committee and conducted at the Clinic
for Lung Diseases and the Center for Medical
Biochemistry of the Clinical Center of Serbia, enrolled
50 COPD patients (28 males/22 females, age
(x⎯ ±SD=49.0±14.5) years, diagnosed according to
the GOLD (Global Initiative for Chronic Obstructive
Lung Disease) criteria (17). Among them, 15 attend-
ed the outpatient department of the Clinic, while 35
were hospitalized and enrolled upon remission
accomplishment. Exclusion criteria were smoking,
alcohol consumption and supplementation with folic
acid and/or vitamin B12, as well as the presence of
coronary heart disease, cerebrovascular and gastroin-
testinal disorders, renal insufficiency, diabetes, malig-
nant or autoimmune disease.
Blood samples were collected into SST® II
Advance tubes (BD Vacutainer, Franklin Lakes, NJ,
USA) following 12 hours of overnight fasting after a
light meal and serum was separated by centrifugation
for 15 minutes at 1500 g (16, 18). The chemilumi-
nescent microparticle immunoassays (CMIA) on the
ARCHITECT® ci8200 Integrated System (Abbott
Diagnostics, Wiesbaden, Germany) was applied for
measurement of homocysteine, folate and vitamin
B12 concentrations.
Kolmogorov-Smirnov, Mann-Whitney U tests
and c2 tests, Spearman’s correlation and ROC
(Receiving Operator Characteristic) analysis were
included in the statistical analysis, performed with
SPSS® Statistic software version 22.0 (IBM®, New
York, USA). Deficiencies of both vitamins were
defined using the abovementioned different cut-offs
from the literature. To test the possibility that these
may be predicted by the occurrence of HHcy, ROC
analyses were performed for HHcy defined as a Hcy
concentration above 10, 12 and 15 mmol/L. These
cut-offs were chosen because they are applied to dis-
tinguish tolerable from increased Hcy concentrations
(19). P values below 0.05 were considered statistical-
ly significant.
Results
The Gaussian mode of distribution was
observed for folate (P=0.200) and vitamin B12
(P=0.200), while this was not the case for Hcy
(P=0.041). The following concentrations (mean (SD)
/median (Q1–Q3)) were measured in patients en -
rolled: folate 4.13 (2.16) mg/L, vitamin B12 463.6
(271.0) ng/L, and Hcy 13.22 (11.48–16.08) mmol/L.
Correlation analyses of the variables investigated
(Table I) revealed an inverse relationship between vita-
min B12 and Hcy concentration as the only one sig-
nificant.
Figure 1 Gender associated differences in concentrations of
folate and vitamin B12.
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Table I Correlation coefficients (R) between the investigated
variables.
Folate, mg/L Vitamin B12, ng/L
Hcy, mmol/L – 0.138 (0.340) – 0.310 (0.029)
Vitamin B12, ng/L 0.008 (0.955) /
P values are given in brackets
Table II Incidence of vitamin deficiencies and the corre-
sponding cut-offs.
Folate
Cut-off (mg/L) 4.0 6.6 8.0
Ratio 16/50 42/50 45/50
Vitamin B12
Cut-off (ng/L) 203 473
Ratio 2/50 29/50
Gender associated differences in concentration
(Figure 1) were not of significance for either vitamin.
Correlation between patients’ age and vitamin con-
centration was characterized with the R=0.279
(P=0.047) for folate and R=–0.103 (P=0.477) in
case of vitamin B12.
The calculated incidence of folate and vitamin
B12 deficiencies differed significantly (P=0.000 and
P<0.000 for folate and vitamin B12 respectively),
depending on which cut-off was used for classifica-
tion (Table II).
ROC analyses failed to show any significance of
HHcy (defined by various Hcy concentrations which
should be exceeded) as a predictor of folate or vita-
min B12 deficiency, regardless of the cut-off used to
define vitamin deficiency. Tables III and IV contain
details about the ROC analysis for folate and vitamin
B12 deficiency, respectively.
Discussion
In the COPD patients enrolled, an inverse rela-
tionship between the concentrations of vitamins and
Hcy was significant only for vitamin B12. This finding
is opposite to the one reported on the basis of values
measured in a group of Italian patients (15) and par-
tially concordant with the results in a group of
patients from North America in whom no significant
association was observed between HHcy and these
vitamins’ intake as estimated from a food frequency
questionnaire (14). Although higher concentrations
of folate were observed in healthy women (6, 10),
gender related differences in COPD patients were not
evaluated previously. Results from this study indicate
that male and female patients have comparable val-
ues of both vitamins. Furthermore, a positive correla-
tion between folate (6, 10) and vitamin B12 (10) lev-
els and age was shown in a healthy population.
However, only a borderline significant correlation with
folate was confirmed in this study.
Average folate and vitamin B12 concentrations
in this study were lower than those measured in a
group of Swedish patients (7.0 mg/L and 540.0 ng/L
for folate and vitamin B12 respectively) (12) and high-
er in comparison with Italian patients (2.5 mg/L and
324.5 ng/L) (15). Nevertheless, significant caution is
recommended when interpreting these differences.
Elderly patients were enrolled in the Swedish study
and information about the methods applied for mea -
surement was not included in the article reporting the
results. In the study conducted in Italy, although the
concentrations were also measured using CMIA, only
patients with no COPD exacerbations 6 months prior
to blood sampling were included.
Prevalence of deficiency in the present study
was highly dependent on the cut-off values used. In
the case of folate, it increased from 32.3%, when
defined with the cut-off of 4.0 mg/L, to 84.0% or even
90.0% with the cut-off set at 6.6 mg/L and 8.0 mg/L
respectively. For vitamin B12, the change of cut-off
from 203 ng/L to 473 ng/L was accompanied by an
increase in the percentage of patients considered
deficient from 4.0% to 58.0%. To consider Swedish
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Table III ROC analysis for prediction of folate deficiency.
Table IV ROC analysis for prediction of vitamin B12 deficiency.
Vitamin 
cut-off 4.0 mg/L 6.6 mg/L 8.0 mg/L
HHcy 
cut-off AUC SE 95% CI P AUC SE 95% CI P AUC SE 95% CI P
10 mmol/L 0.514 0.101 0.317–0.711 0.721 0.552 0.112 0.332–0.773 0.651 0.686 0.109 0.472–0.900 0.229
12 mmol/L 0.556 0.103 0.354–0.757 0.584 0.603 0.113 0.382–0.824 0.375 0.661 0.139 0.389–0.933 0.298
15 mmol/L 0.620 0.094 0.435–0.805 0.235 0.615 0.104 0.410–0.819 0.322 0.671 0.113 0.451–0.892 0.267
Vitamin cut-off 203 ng/L 473 ng/L
HHcy cut-off AUC SE 95% CI P AUC SE 95% CI P
10 mmol/L 0.553 0.267 0.029–1.000 0.859 0.633 0.097 0.443–0.824 0.166
12 mmol/L 0.632 0.224 0.193–1.000 0.657 0.671 0.094 0.487–0.854 0.076
15 mmol/L 0.842 0.108 0.631–1.000 0.248 0.504 0.096 0.316–0.693 0.965
patients as folate deficient, the cut-off was set at 2.64
mg/L and yielded the prevalence of approximately
17%, while a vitamin B12 concentration of 203 ng/L
classified almost 6% as deficient (12).
The ROC analyses, using different vitamin and
Hcy cut-offs, clearly demonstrated that folate or vita-
min B12 deficiency in the investigated group cannot
be predicted by the occurrence of HHcy. Although
this finding might significantly neglect the clinical util-
ity of Hcy measurement in COPD patients, further
consideration could offer additional standpoints. It
may support the hypothesis that intensive methylation
of DNA, RNA and different proteins during lung tis-
sue repair generates high amounts of S-adenosyl-Hcy
and Hcy in the lung tissue and plasma respectively
(20). Despite the fact that this Hcy influx might be
regarded as an epiphenomenon in COPD, not influ-
enced by any traditional determinant of Hcy concen-
tration (20), certain attention should be focused on
the molecular and cellular oxidative damage caused
by HHcy (21). Taken together with the report about
the presence of increased oxidative stress at the
moment of remission accomplishment after COPD
exacerbation (22), it can be assumed that a certain
time span is needed for the vitamins’ depletion, pre-
dictable by HHcy, to develop in these patients.
A rather small number of participants is a limita-
tion of the present study. Although the other studies
addressing »B-vitamins complex« deficiency and its
relationship with the Hcy level included a comparable
number of patients, the results presented should be
interpreted as »pilot« and further evaluation of their
confidence in larger studies is recommended.
The results presented support the conclusion
that the reliability of Hcy concentration as a biomark-
er of folate or vitamin B12 depletion in COPD is not
satisfactory and that their deficiency cannot be pre-
dicted by the occurrence of HHcy.
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